Bruno Chalom Sayada
Algemeen Directeur bij Advanced Biological Laboratories SA
Profiel
Bruno Chalom Sayada is the founder and the Chief Executive Officer of Advanced Biological Laboratories SA, which was founded in 2000.
He is currently the Chairman of Genoscience Pharma, the Managing Director of Humedics GmbH, and the Manager of Hiael SARL.
Dr. Sayada's former positions include being the Chief Executive Officer of Sequoia Pharmaceuticals, Inc., the President & Chief Executive Officer of ActivBiotics, Inc. from 2000 to 2003, the President & Chief Executive Officer of ACT Gene SA from 1996 to 1998, and the Chief Executive Officer of TrioBiotics Pharma AG.
He was also the Chairman-Supervisory Board of Génomic Vision SA from 2008 to 2018, the Chairman & President of Probiox SA, the Managing Director & Director of Integrated Therapeutic Systems SA, and a Director of ActivBiotics Pharma LLC.
Additionally, he served as the Vice President of Visible Genetics, Inc. from 1998 to 2000, the Scientific Manager of Roche Diagnostics Corp.
from 1993 to 1996, and the Manager-Product & Scientific of Roche Diagnostics France SASU from 1993 to 1996.
Actieve functies van Bruno Chalom Sayada
Bedrijven | Functie | Begin |
---|---|---|
Advanced Biological Laboratories SA
Advanced Biological Laboratories SA Packaged SoftwareTechnology Services Advanced Biological Laboratories SA develops information technology and health solutions for patient management and sequencing data analysis. Its products. Its products are marketed under the brands of TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, and HepatiC™. The company was founded by Chalom Bruno Sayada in 2000 and is headquartered in Luxembourg. | Algemeen Directeur | 01-01-2000 |
Hiael SARL | Corporate Officer/Principal | - |
Genoscience Pharma
Genoscience Pharma BiotechnologyHealth Technology Genoscience Pharma is a French clinical-stage biotechnology company that develops novel lysosomotropic therapeutics to establish a new standard of care against cancer, autoimmune, and infectious diseases. The private company is based in Marseille, France and was founded in 2001 by Philippe Halfon. Its lead candidate, GNS561, is a phase 2 ready drug candidate that tackles cancer cells through autophagy modulation. Genoscience Pharma is also entering a phase 2 trial with GNS561. | Voorzitter | - |
Humedics GmbH
Humedics GmbH Packaged SoftwareTechnology Services Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany. | Algemeen Directeur | - |
Eerdere bekende functies van Bruno Chalom Sayada
Bedrijven | Functie | Einde |
---|---|---|
GENOMIC VISION | Voorzitter | 04-07-2018 |
Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Algemeen Directeur | 01-01-2004 |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | Algemeen Directeur | 01-01-2003 |
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Corporate Officer/Principal | 01-01-2000 |
ACT Gene SA
ACT Gene SA Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, ACT Gene SA is a French company that provides diagnostic laboratory services specializing in gene sequencing. The company is based in Paris, France. ACT Gene was acquired by Visible Genetics, Inc. on April 23, 1998 for $1.22 million. | Algemeen Directeur | 01-01-1998 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
GENOMIC VISION | Health Technology |
Bedrijven in privébezit | 14 |
---|---|
Advanced Biological Laboratories SA
Advanced Biological Laboratories SA Packaged SoftwareTechnology Services Advanced Biological Laboratories SA develops information technology and health solutions for patient management and sequencing data analysis. Its products. Its products are marketed under the brands of TherapyEdge®, ViroScore®, SeqHepB, DeepChek®, VisibleChek®, and HepatiC™. The company was founded by Chalom Bruno Sayada in 2000 and is headquartered in Luxembourg. | Technology Services |
Sequoia Pharmaceuticals, Inc.
Sequoia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sequoia Pharmaceuticals discovers and develops unique treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant disease. Most new anti-viral drugs were designed to block the most prevalent form of a pathogen, but these drugs become less potent due to the emergence of drug-resistant mutations. Sequoia's is to discover and develop new antiviral which are active against the most prevalent form of the virus but also anticipates the emergence of drug resistance forms thereby maintaining potency over time. Sequoia's differentiating approach is to identify a constellation of atomic interaction points which are necessary and sufficient for enzymatic function. Sequoia's protease inhibitors have been designed to interact preferentially with only these atoms, thus allowing non-critical mutations to occur without resulting in a decrease in drug potency. The foundation of Sequoia's novel Resistant-Repellent™ technology is a drug discovery tool that enhances the efficiency with which drugs are designed. It is based on an understanding of the chemical and physical nature of the molecular targets, the enzymes and receptors to which drugs bind, combined with an understanding of the molecular mechanisms that cause drug resistance. Sequoia is also discovering and developing a unique series of pharmacokinetic enhancers (PKEs) to work in combination with its own, and its partners', antiviral therapies. These sets of molecules improve the PK of existing therapeutics and reduce interpatient variability. This represents a unique approach to an important need in HIV treatment today. Sequoia is also looking to extend this novel PKE approach to other areas. Its PKEs are designed to inhibit a particular CYP isozyme and therefore change the metabolism of a co-administered therapeutic agent. The combination of PK Enhancer and the therapeutic agent enables reduced dosage and less frequent administration of the therapeutic agent. | Health Technology |
ActivBiotics, Inc.
ActivBiotics, Inc. BiotechnologyHealth Technology ActivBiotics, Inc. discovers and develops pharmaceutical drugs. It provides discovery, development, and commercialization of therapies for the treatment of vascular disease, inflammation, and other high-value chronic and infectious diseases. The company was founded in 1996 and is headquartered in Lexington, MA. | Health Technology |
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Health Technology |
ACT Gene SA
ACT Gene SA Miscellaneous Commercial ServicesCommercial Services Part of Bayer AG, ACT Gene SA is a French company that provides diagnostic laboratory services specializing in gene sequencing. The company is based in Paris, France. ACT Gene was acquired by Visible Genetics, Inc. on April 23, 1998 for $1.22 million. | Commercial Services |
Roche Diagnostics Corp.
Roche Diagnostics Corp. Medical SpecialtiesHealth Technology Roche Diagnostics Corp. develops and manufactures diagnostic products. It offers anticoagulation management, blood gas and electrolytes, cholesterol and urinalysis products. The firm provides a broad portfolio of tools that help healthcare providers in the prevention, diagnosis and management of diseases like HPV, HIV, heart failure and diabetes, as well as other medical conditions, such as fertility and blood coagulation. Its products and services uses by researchers, physicians, patients, hospitals and laboratories worldwide. The company was founded in 1964 by Willard Eason and is headquartered in Indianapolis, IN. | Health Technology |
Probiox SA
Probiox SA Miscellaneous Commercial ServicesCommercial Services Probiox SA engages in the development and commercialization of solutions based on oxidative stress markers. The firm owns intellectual property related to the analysis and interpretation of oxidative stress parameters. It also provides turnkey solutions to companies for the evaluation of the antioxidant/anti-inflammatory properties of their products. The company's services include intellectual deliveries (literature reviews and scientific records for starting projects, registrations, claims, marketing support and scientific survey), clinical studies (assessment of oxidative stress in the context of existing studies or conducting turnkey studies) and In Vitro studies. Probiox was founded in 2001 and is headquartered in Liege, Belgium. | Commercial Services |
TrioBiotics Pharma AG
TrioBiotics Pharma AG Pharmaceuticals: MajorHealth Technology TrioBiotics Pharma AG manufactures pharmaceuticals for the treatment of psychiatric, cancer and infectious diseases. It offers anti-infectives for chronic and infectious disease markets. The company is headquartered in Zurich, Switzerland. | Health Technology |
Integrated Therapeutic Systems SA
Integrated Therapeutic Systems SA Information Technology ServicesTechnology Services Integrated Therapeutic Systems SA develops information for applications in the healthcare and science sectors. The company was founded on January 20, 2006 and is headquartered in Sprimont, Belgium. | Technology Services |
Hiael SARL | |
ActivBiotics Pharma LLC
ActivBiotics Pharma LLC Miscellaneous Commercial ServicesCommercial Services ActivBiotics Pharma LLC is a private company that researches pharmaceutical products. The company is based in Tucker, GA. | Commercial Services |
Roche Diagnostics France SASU
Roche Diagnostics France SASU Medical SpecialtiesHealth Technology Roche Diagnostics develops test and diagnostic solutions in vitro to serve the patients. The company was founded on February 4, 1991 and is headquartered in Meylan, France. | Health Technology |
Genoscience Pharma
Genoscience Pharma BiotechnologyHealth Technology Genoscience Pharma is a French clinical-stage biotechnology company that develops novel lysosomotropic therapeutics to establish a new standard of care against cancer, autoimmune, and infectious diseases. The private company is based in Marseille, France and was founded in 2001 by Philippe Halfon. Its lead candidate, GNS561, is a phase 2 ready drug candidate that tackles cancer cells through autophagy modulation. Genoscience Pharma is also entering a phase 2 trial with GNS561. | Health Technology |
Humedics GmbH
Humedics GmbH Packaged SoftwareTechnology Services Humedics GmbH operates as a research-based medtech company. It focuses on rapid and precise lover function measurement using LiMax, a breath analysis technology. The company was founded by Martin Stockman, Erwin de Bujizer, and Karsten Heyne in 2009 and is headquartered in Berlin, Germany. | Technology Services |